MissionIR's  Instablog

Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
My blog:
MissionIR Blog
  • OxySure Systems, Inc. (OXYS) Cuts Q3 Loss, Achieves Third Consecutive Quarter Of Growth As Sales Increase 428 Percent 0 comments
    Nov 14, 2013 3:08 PM | about stocks: OXYS

    OxySure Systems, a medical technology company focused on the design, manufacture, and distribution of specialty respiratory and medical solutions, today in its third-quarter financial and operating results posted its third consecutive quarter of triple-digit revenue growth and a narrowed net loss.

    "We had an excellent building quarter and we are pleased to have sustained our positive momentum for the year so far," Julian T. Ross, CEO of OxySure stated in the news release. "Our results for the third quarter reflect our continued success at executing on strategic initiatives aimed at generating superior top-line growth while staying focused on controlling our expenses. We plan to continue our strategy of building awareness for our new and innovative lifesaving products, while investing in branding, distribution, R&D and sales. We are excited about some of the initiatives we are currently working on."

    Total revenues for the quarter increased 428 percent to $545,820, as compared to revenues of $103,327 in the third quarter of last year.

    Gross profit increased approximately 722 percent to $434,710 from $52,855 a year ago.

    The company cut its net loss by approximately 38.3 percent to $82,613, or $0.00 per share, from a net loss of $133,779, or a loss of $0.01 per share, reported in the year ago period.

    Selling, general, and administrative expenses increased to $478,518 from $206,810 for the comparable quarter of 2012, reflecting ramped up sales and marketing expenses as the company worked to expand its sales and branding efforts. Research and development expense during the third quarter of 2013 was $134,357 as compared to $579 for the third quarter of last year.

    OxySure said it continues to execute on its core growth strategy to grow its sales and distribution both domestically and abroad, and recapped key milestones of 2013, including new distribution agreements and product launch.

    For more information, visit OxySure.com

    MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.missionir.com

    Stocks: OXYS
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.